Home / Market News / $ABBV
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Analysts Adjust Price Targets for AbbVie

Nov 2, 2026, 12:34 PM UTC · Primary ticker $ABBV

Multiple investment banks, including RBC Capital Markets, Cantor Fitzgerald, and Guggenheim, have increased their price targets for AbbVie. These adjustments reflect updated analyst valuations and perspectives on the company's market position, suggesting a positive outlook from these firms.

On November 2, 2026, RBC Capital Markets, Cantor Fitzgerald, and Guggenheim all raised their price targets for AbbVie. RBC increased its target to $330 from $280, Cantor to $325 from $290, and Guggenheim to $322 from $288, with RBC maintaining an 'Outperform' rating. This indicates a more optimistic view from these analysts regarding AbbVie's future performance and valuation. For traders, this could signal short-term positive sentiment and potentially upward price momentum for ABBV, as higher price targets often attract investor interest. The long-term implications depend on whether the company's fundamentals align with these elevated expectations, with the key opportunity being potential capital appreciation if the market converges with these new targets.

$ABBV positive Analyst price target increases
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.